- Study Objective: Investigate the relationship between complete posterior vitreous detachment (PVD) and clinical outcomes in central retinal vein occlusion (CRVO) patients.

- Methods: Retrospective longitudinal cohort study of 102 acute, treatment-naive CRVO patients (2009-2021) with ≥12 months follow-up. Eyes stratified by presence or absence of complete PVD on optical coherence tomography (OCT).

- Key Findings:

  - Complete PVD Prevalence: 51% (52 eyes) had complete PVD at presentation.

  - Central Subfield Thickness (CST): Significantly lower in complete PVD eyes at 12 months (284.9 ± 122.9 μm vs. 426.8 ± 286.4 μm, \( P < 0.001 \)) and final follow-up (278 ± 127.9 μm vs. 372.8 ± 191.0 μm, \( P = 0.022 \)).

  - Cystoid Macular Edema (CME): Lower incidence in complete PVD eyes at 12 months (32% vs. 65%, \( P = 0.002 \)) and final follow-up (28.8% vs. 48%, \( P = 0.045 \)).

  - Injection Burden: Complete PVD eyes required fewer intravitreal anti-VEGF injections in the first year (5.1 ± 3.6 vs. 6.7 ± 3.3, \( P = 0.013 \)).

  - Neovascularization (NV): No significant difference in NV rates between complete and incomplete PVD groups.

  - Visual Acuity (VA): No significant difference in VA between groups at presentation, 12 months, or final follow-up.

- Demographics:

  - Complete PVD patients were older (74.4 ± 11.9 years vs. 61.1 ± 13.1 years, \( P < 0.001 \)).

  - No significant differences in sex, race, systemic diseases, or CRVO perfusion status between groups.

- Discussion:

  - Complete PVD may reduce CME and injection burden by decreasing proinflammatory cytokines at the vitreomacular interface.

  - Vitreopapillary adhesion (stage 3 PVD) may still exert mechanical or inflammatory effects similar to incomplete PVD.

  - Study limitations include reliance on spectral-domain OCT and not accounting for eyes that developed complete PVD during follow-up.

- Conclusion: Complete PVD in CRVO is associated with better outcomes, including lower CST, reduced CME, and fewer anti-VEGF injections. OCT assessment of the vitreomacular interface may serve as a prognostic biomarker in CRVO.